National Cancer Institute "Cancer Moonshot Biobank"

Eligibility Criteria

• * Is consistent with OR has been diagnosed with one of the following:
• * Colorectal cancer: Stage IV
• * Non-small cell or small cell lung cancer: stage III/IV
• * Prostate cancer: metastatic prostate cancer
• * Gastric cancer, not otherwise specified (NOS): stage IV
• * Esophageal cancer, NOS: stage IV
• * Adenocarcinoma of gastroesophageal junction: stage IV
• * High grade serous ovarian cancer: stage III/IV
• * Invasive breast carcinoma: stage III/IV
• * Melanoma: stage III/IV
• * Acute myeloid leukemia
• * Multiple myeloma
• * For the purposes of this study, re-staging is allowed
• * Patient should fit in one of the following four clinical scenarios (a-d)
• * Undergoing diagnostic workup for one of the diseases listed for which treatment will likely include a new regimen of standard of care therapy OR
• * Scheduled to begin treatment with a new regimen of standard of care therapy OR
• * Currently progressing on a regimen of standard of care therapy OR
• * Currently being treated with a regimen standard of care therapy, without evidence of progression
• * Requirements for fresh tissue biospecimen collections at enrollment:
• * For clinical scenarios a, b, and c above, freshly collected tumor tissue or bone marrow (BM) aspirate must be submitted at enrollment
• * For clinical scenarios a and b, the fresh tissue collection must be prior to starting therapy
• * For clinical scenario a, the biospecimen collection must be part of a standard of care medical procedure
• * For clinical scenarios b or c, the biospecimen collection may be part of a standard of care medical procedure OR
• * The biospecimen collection may be part of a study-specific procedure ("research only biopsy"), when the patient has a tumor amenable to image guided or direct vision biopsy and is willing and able to undergo a tumor biopsy for molecular profiling
• * Note: For research-only biopsies, the biopsy must not be associated with a significant risk of severe or major complications or death; the procedure cannot be a mediastinal, laparoscopic, open or endoscopic biopsy; nor can the procedure be a brain biopsy; nor can the patient be under the age of majority as determined by each U.S. state
• * Requirements for archival tissue:
• * For clinical scenarios a and b above, archival tissue as outlined below must be submitted IF AVAILABLE
• * For clinical scenarios c and d above, archival tissue as outlined below is REQUIRED
• * Pre-existing archival material (formalin-fixed, paraffin-embedded \[FFPE\] block, BM aspirate, or unstained slides) that:
• * Contains the cancer type for which the participant is enrolled, and
• * Was collected no more than 5 years prior to initiation of therapy, and
• * Contains at least a surface area of 5 mm\^2 and optimum surface area of 25 mm\^2 or 3-5 mL cryopreserved bone marrow aspirate to yield 200 million bone marrow mononuclear cells, and
• * No more than 1 line of standard of care systemic therapy was administered from the date of archival material collection to the date of initiation of therapy
• * Requirements for blood collection: ALL scenarios require fresh blood collection at enrollment
• * Blood collection for clinical scenarios a, b, and c must take place within 1 week of fresh tumor specimen collection
• * Blood collection for clinical scenario d must take place within 4 weeks of enrollment
• * Age 13 or older
• * Any sex and any gender
• * Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2
• * Ability to understand and willingness to sign an informed consent document. Consent may be provided by a Legally Authorized Representative (LAR) in accordance with 45 CFR 46.102(i)
• * Treated with or has already begun treatment with a non-standard of care therapeutic agent (investigational) in an interventional clinical trial
• * Uncontrolled intercurrent illness that in the physician's assessment would pose undue risk for biopsy
• * Use of full dose coumarin-derivative anticoagulants such as warfarin are prohibited. Patients may be switched to low molecular weight (LMW) heparin at physician discretion
• * Low molecular weight (LMW) heparin is permitted for prophylactic or therapeutic use
• * Factor X inhibitors are permitted
• * Use of anti-platelet drugs are permitted
• * Stopping the anticoagulation treatment for biopsy, bone marrow aspirate, or resection should be per site standard operating procedure (SOP)
• * NCI PDMR